CCO Independent Conference Coverage

Slides:



Advertisements
Similar presentations
May 29 - June 2, 2015 Atezolizumab (MPDL3280A) Shows Favorable Tolerability, Promising Activity in Urothelial Bladder Cancer CCO Independent Conference.
Advertisements

Phase II Study: Pembrolizumab + Pomalidomide/Dexamethasone for Patients With R/R MM New Findings in Hematology: Independent Conference Coverage* of ASH.
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 GOG0213: Bevacizumab Retreatment of Recurrent Platinum-Sensitive Ovarian.
MA.17R: Reduced Risk of Recurrence With Extending Adjuvant Letrozole Beyond 5 Yrs in Postmenopausal Women With Early-Stage Breast Cancer CCO Independent.
POPLAR: Atezolizumab Improved Survival vs Docetaxel in Patients With Advanced NSCLC and Increasing Levels of PD-L1 Expression CCO Independent Conference.
KEYNOTE-021: Pembrolizumab + Ipilimumab Active in Previously Treated Advanced NSCLC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 Phase II MONARCH 1: CDK4/6 Inhibitor Abemaciclib in HR+/HER2- MBC.
May 29 - June 2, 2015 KEYNOTE-028: Antitumor Activity With Pembrolizumab in Patients With PD-L1- Positive Extensive-Stage SCLC CCO Independent Conference.
CCO Independent Conference Coverage
CCO Independent Conference Coverage
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 Fractionated Dosing Optimizes CAR T-Cell Therapy in Adult Relapsed/Refractory.
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 Rovalpituzumab Tesirine Safe, Active in Previously Treated SCLC *CCO.
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 KRISTINE: Neoadjuvant T-DM1 + Pertuzumab vs Chemotherapy With Trastuzumab.
Phase I/II CheckMate 032: Nivolumab ± Ipilimumab in Advanced SCLC
CCO Independent Conference Highlights
KEYNOTE-045: Updated Survival Analysis of Phase III Trial of Pembrolizumab vs Paclitaxel, Docetaxel, or Vinflunine in Pts With Advanced Urothelial Carcinoma.
KEYNOTE-059 (Cohort 1): Pembrolizumab Monotherapy in Previously Treated Advanced Gastric or GEJ Adenocarcinoma CCO Independent Conference Highlights* of.
CCO Independent Conference Highlights
MONARCH 2: Phase III Study of Abemaciclib + Fulvestrant in HR+/HER2- Advanced Breast Cancer After Progression on Endocrine Therapy CCO Independent Conference.
CCO Independent Conference Coverage
Phase II SAKK 35/10 Trial: Rituximab Plus Lenalidomide Shows Durable Activity in Untreated Follicular Lymphoma New Findings in Hematology: Independent.
CCO Independent Conference Highlights
CCO Independent Conference Highlights
: Mogamulizumab in R/R Adult T-Cell Leukemia-Lymphoma
KEYNOTE-028: Pembrolizumab in PD-L1+, ER+/HER2- Breast Cancer
Phase II HALO-202: nab-Paclitaxel and Gemcitabine ± PEGPH20 in Untreated Metastatic Pancreatic Ductal Adenocarcinoma CCO Independent Conference Highlights*
CCO Independent Conference Highlights
PALOMA-2: Addition of Palbociclib to Frontline Letrozole Significantly Improves PFS in Postmenopausal ER+/HER2- Advanced Breast Cancer CCO Independent.
CCO Independent Conference Coverage
Neoadjuvant Palbociclib + Anastrozole in ER+/HER2- Breast Cancer
CCO Independent Conference Highlights
CCO Independent Conference Highlights
19-28z CAR T-Cell Efficacy and Toxicity in Adults With R/R B-Cell ALL
KEYNOTE-086 (Cohort A): Phase II Evaluation of Pembrolizumab Monotherapy in Heavily Pretreated Metastatic TNBC CCO Independent Conference Highlights* of.
CCO Independent Conference Coverage
CCO Independent Conference Coverage
Lenalidomide Shows Promising Activity in Recurrent CNS Lymphoma
CCO Independent Conference Coverage
ELOQUENT-2: Elotuzumab + Len/Dex in R/R MM
CCO Independent Conference Coverage
IMvigor 210 (Cohort 1): First-line Atezolizumab in Cisplatin-Ineligible Metastatic Urothelial Carcinoma CCO Independent Conference Coverage* of the 2016.
Immunoscore Prognostic in Colon Cancer
Phase II PCYC-1121 Trial: Ibrutinib Monotherapy Active in R/R Marginal Zone Lymphoma New Findings in Hematology: Independent Conference Coverage of ASH.
ECHO-204: Preliminary Results of Phase I/II Trial of Epacadostat + Nivolumab in Advanced Solid Tumors CCO Independent Conference Highlights* of the 2017.
CCO Independent Conference Coverage
ASPEN: Prolonged PFS With Sunitinib vs Everolimus in Nonclear-Cell RCC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 -
CCO Independent Conference Highlights
STAMPEDE: Docetaxel Significantly Improves Survival in Men With Hormone-Naive Prostate Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual.
KEYNOTE-052: Updated Findings on First-line Pembrolizumab in Cisplatin-Ineligible Advanced Urothelial Cancer CCO Independent Conference Highlights* of.
New Findings in Hematology: Independent Conference Coverage
Phase I/II Study of Lorlatinib in Advanced ALK+ or ROS1+ NSCLC
Maintenance Lapatinib After Chemotherapy in HER1/2-Positive Metastatic Bladder Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*
CCO Independent Conference Coverage
CCO Independent Conference Coverage
Phase III EMN02/HO95 MM Trial: Upfront ASCT Prolongs PFS vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed MM CCO Independent Conference Coverage*
NCI/CTEP 7435: Eribulin Active, Tolerable in Urothelial Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 - June 2,
New Findings in Hematology: Independent Conference Coverage
SIRveNIB: Randomized Phase III Trial of Selective Internal Radiation Therapy vs Sorafenib in Locally Advanced HCC CCO Independent Conference Highlights*
KEYNOTE-087: Pembrolizumab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma New Findings in Hematology: Independent Conference Coverage.
CCO Independent Conference Highlights
ESPAC-4: Adjuvant Gemcitabine/ Capecitabine Improves 5-Yr Survival vs Gemcitabine Alone in Resected Pancreatic Ductal Carcinoma CCO Independent Conference.
CCO Independent Conference Coverage
Combined Inhibition of PD-L1, MEK, and BRAF Active in Advanced Melanoma CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 -
KEYNOTE-012: Durable Efficacy With Pembrolizumab in PD-L1–Positive Gastric Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*
KEYNOTE-023: Pembrolizumab + Lenalidomide + Dexamethasone Shows Promising Activity and Safety in R/R MM CCO Independent Conference Coverage* of the 2016.
Phase Ib MMY1001: Daratumumab Plus Pom/Dex for Patients With R/R MM
CheckMate 204: Nivolumab + Ipilimumab in Pts With Advanced Melanoma and Asymptomatic, Untreated Brain Metastases CCO Independent Conference Highlights*
CCO Independent Conference Coverage
Trifluridine/Tipiracil (TAS-102) Improves Survival in Patients With Metastatic CRC and Mild Renal/Hepatic Impairment: Subgroup Analysis of RECOURSE CCO.
CCO Independent Conference Coverage
Presentation transcript:

KEYNOTE-029 Expansion Cohort: Pembrolizumab + Ipilimumab Safe, Active in Advanced Melanoma CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 *CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs. This activity is supported by educational grants from Amgen, Ariad, Bayer Healthcare Pharmaceuticals, Celgene Corporation, Genentech, Incyte, Merck, and Taiho Pharmaceuticals.

KEYNOTE-029: Pembrolizumab + Ipilimumab in Advanced Melanoma: Background Rationale for CTLA-4 and PD-1/PD-L1 blockade in melanoma well established[1] CTLA-4 inhibition (eg, by ipilimumab) effective during priming phase PD-1/PD-L1 inhibition (eg, by pembrolizumab, nivolumab) effective at tumor bed during effector phase Pembrolizumab and nivolumab demonstrate improved survival outcomes vs ipilimumab[2,3] Nivolumab 1 mg/kg + ipilimumab 3 mg/kg in combination improved PFS, ORR vs either as monotherapy, but with increased toxicity[3,4] KEYNOTE-029 expansion cohort study evaluated safety, efficacy of pembrolizumab 2 mg/kg + ipilimumab 1 mg/kg in pts with advanced melanoma[5] 1. Ribas A. N Engl J Med. 2012;366:2517-2519. 2. Robert C, et al. N Engl J Med. 2015;372:2521-2532. 3. Larkin J, et al. N Engl J Med. 2015;373:23-34. 4. Postow MA, et al. N Engl J Med. 2015;372:2006-2017. 5. Long GV, et al. ASCO 2016. Abstract 9506. Slide credit: clinicaloptions.com

KEYNOTE-029: Study Design Phase I trial Dose Run-In (Phase Ia)[1] Dose Expansion (Phase Ib)[2] Pts with advanced melanoma, ≥ 0 prior therapies OR pts with advanced RCC, ≥ 1 prior therapy Pts with advanced melanoma; ECOG PS 0-1; ≥ 0 prior therapies, no prior PD-1, PD-L1, or anti–CTLA-4 (N = 153) Pembrolizumab 2 mg/kg Q3W, ≤ 24 mos + Ipilimumab 1 mg/kg Q3W x 4 doses Dose run-in (phase Ia): dose determined to be tolerable, active based on DLT rate[1] Dose expansion (phase Ib)[2] Primary endpoint: safety Secondary endpoints: DoR, ORR, OS, PFS DLT, dose-limiting toxicity; DoR, duration of response; ECOG, Eastern Cooperative Oncology Group; PS, performance score; RCC, renal cell carcinoma; 1. Atkins MB, et al. ASCO 2016. Abstract 3013. 2. Long GV, et al. ASCO 2016. Abstract 9506. Slide credit: clinicaloptions.com

KEYNOTE-029: Baseline Characteristics Pembrolizumab + Ipilimumab (N = 153) Median age, yrs (range) 60 (22-82) Male, % 66 ECOG PS 0, % 74 LDH level elevated, % 24 BRAFV600 mutant, % 36* PD-L1 positive, % 83† M1c disease, % 56 No previous therapy, % 87 ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; PS, performance status. *13 pts with prior BRAF ± MEK inhibitor therapy. †2 pts with tumors not evaluable for PD-L1 expression. PD-L1 positivity defined as ≥ 1% staining in tumor, adjacent immune cells by IHC (22C3 antibody). Slide credit: clinicaloptions.com Long GV, et al. ASCO 2016. Abstract 9506.

KEYNOTE-029: Adverse Events Category, % Treatment Related (N = 153) Immune Mediated* Any grade 95 58 Grade 3/4 42 25 Led to death Led to ipilimumab discontinuation only 10 8 Led to pembrolizumab discontinuation† 7 4 Led to ipilimumab and pembrolizumab discontinuation‡ *Regardless of investigator attribution. †After discontinuation or completion of ipilimumab. ‡Includes 1 pt who discontinued ipilimumab (due to colitis) and then pembrolizumab (due to increased lipase). 72% of pts received all 4 doses of ipilimumab Slide credit: clinicaloptions.com Long GV, et al. ASCO 2016. Abstract 9506.

KEYNOTE-029: Adverse Events Treatment-Related AEs (> 15% Pts), % Any Grade (N = 153) Grade 3/4 Fatigue 46 Pruritus 39 Rash 3 Diarrhea 24 < 1 Lipase increased 18 14 Vitiligo Dry mouth 16 Nausea Hypothyroidism Immune-Mediated AEs per Pt, % Any Grade (N = 153) Grade 3/4 42 75 1 31 22 2 19 3 7 4 < 1 Most common immune-mediated AEs: hypothyroidism, hyperthyroidism, hypophysitis, pneumonitis, hepatitis, colitis, and skin reactions 145 total events were managed with systemic treatment* with corticosteroids (57%), infliximab (7%), or other (4%) 76% of any grade AEs and 81% of grade 3/4 AEs had resolved† at data cutoff AE, adverse event. * ≥ 1 systemic treatments allowed. †Excluding endocrinopathies. Slide credit: clinicaloptions.com Long GV, et al. ASCO 2016. Abstract 9506.

Pembrolizumab + Ipilimumab (N = 153) KEYNOTE-029: Response Characteristic Pembrolizumab + Ipilimumab (N = 153) ORR, % (95% CI) 57 (49-65) DCR, % (95% CI) 78 (71-85) Best overall response, % CR 10 PR 47 SD 22 PD 20 No assessment 2 DCR, disease control rate; PD, progressive disease; SD, stable disease. 81% of pts experienced some tumor reduction; median change: -54.5% Tumor response in both PD-L1–positive or PD-L1–negative status 98% of responders maintained response at time of data cutoff Robust responses experienced in all subgroups Slide credit: clinicaloptions.com Long GV, et al. ASCO 2016. Abstract 9506.

KEYNOTE-029: PFS and OS 70% of pts progression free at 6 mos Events: 49 (32%) Median PFS: NR 93% of pts alive at 6 mos Median OS: NR Median follow-up: 10.0 mos (range: 0.8-14.1 mos) NR, not reached. Slide credit: clinicaloptions.com Long GV, et al. ASCO 2016. Abstract 9506.

KEYNOTE-029: Conclusions Combination of pembrolizumab 2 mg/kg + ipilimumab 1 mg/kg appears to have manageable toxicity profile 72% of pts received all 4 doses of ipilimumab Grade 3/4 immune-mediated AEs: 25% No treatment-related deaths Pembrolizumab 2 mg/kg + ipilimumab 1 mg/kg produces robust, durable responses in pts with advanced melanoma ORR: 57% ORR similar across key subgroups Durable response in 98% of pts DoR: 6+ to 43+ wks; 6-mo PFS: 70% AE, adverse event; DoR, duration of response. Slide credit: clinicaloptions.com Long GV, et al. ASCO 2016. Abstract 9506.

Go Online for More CCO Coverage of ASCO 2016! Short slideset summaries of all the key data Additional CME-certified analyses with expert faculty commentary on all the key studies in: Breast, Genitourinary, and Lung cancers Hematologic malignancies Immunotherapy clinicaloptions.com/oncology